T
Tom Rolf
Researcher at Infectious Disease Research Institute
Publications - 4
Citations - 275
Tom Rolf is an academic researcher from Infectious Disease Research Institute. The author has contributed to research in topics: Antigen & Adjuvant. The author has an hindex of 4, co-authored 4 publications receiving 190 citations.
Papers
More filters
Journal ArticleDOI
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.
Rhea N. Coler,Malcolm S. Duthie,Kimberly A. Hofmeyer,Jeffery Guderian,Lakshmi Jayashankar,Julie Vergara,Tom Rolf,Ayesha Misquith,John D. Laurance,Vanitha S. Raman,H. Remy Bailor,Natasha Dubois Cauwelaert,Steven J. Reed,Aarthy C. Vallur,Michelle Favila,Mark T. Orr,Jill A. Ashman,Prakash Ghosh,Dinesh Mondal,Steven G. Reed +19 more
TL;DR: The vaccine candidate was shown to be safe and induced a strong antigen‐specific immune response, as evidenced by cytokine and immunoglobulin subclass data, which provide a strong rationale for additional trials in Leishmania‐endemic countries in populations vulnerable to VL.
Journal ArticleDOI
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
Rhea N. Coler,Tracey A. Day,Ruth D. Ellis,Franco M. Piazza,Anna Marie Beckmann,Julie Vergara,Tom Rolf,Lenette L. Lu,Galit Alter,David A. Hokey,Lakshmi Jayashankar,Robert L. Walker,Margaret A Snowden,Thomas J. Evans,Ann M. Ginsberg,Steven G. Reed +15 more
TL;DR: A tuberculosis vaccine containing an immunity-potentiating agent stimulated strong immune responses in a first-in-human trial and demonstrated an acceptable safety profile and indicated that the GLA-SE adjuvant drives a functional humoral and T-helper 1 type cellular response.
Journal ArticleDOI
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Tracey A. Day,Adam Penn-Nicholson,Angelique Kany Kany Luabeya,Andrew Fiore-Gartland,Nelita du Plessis,Andre G. Loxton,Julie Vergara,Tom Rolf,Timothy D. Reid,Asma Toefy,Justin Shenje,H. Geldenhuys,Michele Tameris,Simbarashe Mabwe,Nicole Bilek,Linda-Gail Bekker,Andreas H. Diacon,Gerhard Walzl,Jill A. Ashman,Aude Frevol,Zachary K. Sagawa,Cecilia S. Lindestam Arlehamn,Alessandro Sette,Steven G. Reed,Rhea N. Coler,Rhea N. Coler,Thomas J. Scriba,Mark Hatherill,Anna Marie Beckmann,Fan-Chi Hsu,Sarah Albertson,Ashley Veldsman,Constance Schreuder,Erica Smit,Yolundi Cloete,Cynthia Ontong,Elisabeth Filander,Gail Jacobs,Alana Keyser,Hadn Africa,Humphrey Mulenga,Julia Noble,Lebohang Makhethe,Marcia Steyn,Marwou de Kock,Nambitha Quaqua,Yiwen Lu,Andrea Gutschmidt,Friedrich Thienemann,Stuart Kahn,Angelique Mouton,Elma Van Rooyen,Fajwa Opperman,Ann Swarts,Amaryl Van Schalkwyk,Yolandi Herselman,Devona Hofmeester,Julia Amsterdam,Leya Hassanally,Linda van der Merwe,Alessandro Companie,Susan Rossouw,Carolyn Jones,Natasja Botes,Elize van der Riet,Sandra Goliath,Sandra Kruger,Eunice Sinandile +67 more
TL;DR: The ID93’s+ GLA-SE vaccine induced robust and durable antibody responses and specific, polyfunctional CD4 T-cell responses to vaccine antigens, and the primary outcomes were safety and immunogenicity.
Journal ArticleDOI
A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults.
Malcolm S. Duthie,Aude Frevol,Tracey A. Day,Rhea N. Coler,Julie Vergara,Tom Rolf,Zachary K. Sagawa,Anna Marie Beckmann,Corey Casper,Steven G. Reed +9 more
TL;DR: Healthy United States-based adult volunteers with no history of travel to leprosy-endemic countries were enrolled for the first-in-human evaluation of LepVax, and immunological analyses indicated that similar LEP-F1-specific antibody and Th1 cytokine secretion were induced by each of the antigen doses evaluated within LepVX.